Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

April 21, 2023

Study Completion Date

April 25, 2023

Conditions
Metastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis and Ureter Urothelial CarcinomaMetastatic Ureter Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
DRUG

Berzosertib

Given IV

DRUG

Cisplatin

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

Trial Locations (39)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

22908

University of Virginia Cancer Center, Charlottesville

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

27710

Duke University Medical Center, Durham

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

37204

Vanderbilt Breast Center at One Hundred Oaks, Nashville

37232

Vanderbilt University/Ingram Cancer Center, Nashville

40536

University of Kentucky/Markey Cancer Center, Lexington

43210

Ohio State University Comprehensive Cancer Center, Columbus

44106

Case Western Reserve University, Cleveland

48201

Wayne State University/Karmanos Cancer Institute, Detroit

48334

Weisberg Cancer Treatment Center, Farmington Hills

53792

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

55905

Mayo Clinic in Rochester, Rochester

63110

Washington University School of Medicine, St Louis

63129

Siteman Cancer Center-South County, St Louis

63136

Siteman Cancer Center at Christian Hospital, St Louis

63141

Siteman Cancer Center at West County Hospital, Creve Coeur

66205

University of Kansas Clinical Research Center, Fairway

University of Kansas Hospital-Westwood Cancer Center, Westwood

68118

Nebraska Medicine-Village Pointe, Omaha

68123

Nebraska Medicine-Bellevue, Bellevue

68198

University of Nebraska Medical Center, Omaha

80045

UCHealth University of Colorado Hospital, Aurora

85054

Mayo Clinic Hospital in Arizona, Phoenix

85259

Mayo Clinic in Arizona, Scottsdale

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

91105

Keck Medical Center of USC Pasadena, Pasadena

92663

USC Norris Oncology/Hematology-Newport Beach, Newport Beach

94304

Stanford Cancer Institute Palo Alto, Palo Alto

95817

University of California Davis Comprehensive Cancer Center, Sacramento

32224-9980

Mayo Clinic in Florida, Jacksonville

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02567409 - Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer | Biotech Hunter | Biotech Hunter